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Abstract
To study the effects of transforming growth factor beta 1 (TGF-b1) on fibrosis and failure of regeneration of skeletal muscles,
we generated a tet-repressible muscle-specific TGF-b1 transgenic mouse in which expression of TGF-b1 is controlled by oral
doxycycline. The mice developed muscle weakness and atrophy after TGF-b1 over-expression. We defined the group of
mice that showed phenotype within 2 weeks as early onset (EO) and the rest as late onset (LO), which allowed us to further
examine phenotypic differences between the groups. While only mice in the EO group showed significant muscle weakness,
pathological changes including endomysial fibrosis and smaller myofibers were observed in both groups at two weeks after
the TGF-b1 was over-expressed. In addition, the size of the myofibers and collagen accumulation were significantly different
between the two groups. The amount of latent and active TGF-b1 in the muscle and circulation were significantly higher in
the EO group compared to the LO or control groups. The up-regulation of the latent TGF-b1 indicated that endogenous
TGF-b1 was induced by the expression of the TGF-b1 transgene. Our studies showed that the primary effects of TGF-b1
over-expression in skeletal muscles are muscle wasting and endomysial fibrosis. In addition, the severity of the pathology is
associated with the total amount of TGF-b1 and the expression of endogenous TGF-b1. The findings suggest that an autofeedback loop of TGF-b1 may contribute to the severity of phenotypes.
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complex is transported to the ECM and is the major form of TGFb1 found in vivo [19,20]. LTBPs interact with various matrix
components including collagen and fibronectin [21]. TGF-b1
must be released from this complex before it can interact with
TGF-b receptors. During latent TGF-b1 activation, the TGF-b1 is
released from LAP.
TGF-b1 is up-regulated in muscles of Duchene muscular
dystrophy (DMD), Congenital muscular dystrophy, and Inflammatory myositis [5,22], and TGF-b mRNA expression was
correlated with the severity of fibrosis in dystrophic muscles [5].
It was reported to be localized in myofibers and perimysial
connective tissue. Our previous temporal expression profiling
study showed that genes involved in TGF-b pathway were upregulated at the symptomatic stage of DMD but not differentially
expressed at the asymptomatic stage, suggesting that the activation
of TGF-b1 pathways was secondary to the primary dystrophin
deficiency and may play a critical role in the fibrosis and failure of
muscle regeneration in DMD [23]. In addition, suppressing the
TGF-b1 pathway in mdx mice, a mouse model of DMD, has been
shown to improve disease phenotypes [24,25]. To clearly define
the effect of TGF-b1 over-expression in healthy skeletal muscles,
we generated and characterized a tet-repressible muscle-specific
transgenic TGF-b1 mouse in which the over-expression of TGF-b1
is restricted in skeletal muscles and can be controlled by oral

Introduction
Transforming growth factor beta 1 (TGF-b1) belongs to a
family of multifunctional cytokines including bone morphogenic
proteins (BMPs) and activins [1]. TGF-b1 plays essential roles in
various biological processes, including cell growth, differentiation,
apoptosis, tissue development, and inflammation [1,2,3]. TGF-b1
stimulates synthesis of extracellular matrix (ECM) proteins and
inhibits matrix degradation, resulting in the promotion of fibrosis
and tissue repair. This phenomenon has been proposed to play a
central role in fibrotic tissue development in certain lung, muscle,
hypertensive vascular, and diabetic renal diseases [4,5,6,7,8,9,10].
Besides its fibrogenic effects, studies showed that TGF-b1 is also a
potent inhibitor of growth and differentiation of myoblasts and
vascular smooth muscle cells (VSMCs) [11,12,13], and can
suppress division and block fusion of satellite cells both in vitro
and
in vivo
through
suppressing
myogenic
factors
[11,12,14,15,16,17,18].
After TGF-b1 is translated, it is cleaved by intracellular
proteolytic processes. The N-terminus of the propeptide, also
known as latency associated peptide (LAP), keeps the TGF-b1
latent. The TGF-b1 is secreted as part of an inactive tripartite
complex consisting of a homodimer of the TGF-b1 with LAP, and
a molecule of latent TGF binding protein (LTBP) [19]. The
PLOS ONE | www.plosone.org
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administration of doxycycline. The findings will help us determine
the contribution of TGF-b1 to the pathologies including fibrosis
and failure of regeneration seen in muscle disorders.

as late onset (LO). This allows us to further examine the
differences in muscle strength and pathology in these mice.

The mCK-tTA/TRE-TGF-b1 Mice Developed Muscle
Weakness and Myofibers Atrophy after the TGF-b1
Transgene was Induced

Results
To confirm muscle-specific expression, we first detected the
expression of TGF-b1 transgene in the mCK-tTA/TRE-TGF-b1
mice by RT-PCR. TGF-b1 mRNA was detected in muscles,
including quadriceps and diaphragm after the transgene was
induced for 2 weeks. Transgene expression was not detected in
other organs examined including heart, brain, kidney, liver,
ovaries, and lung (Figure 1A).
To characterize the phenotype of the mCK-tTA/TRE-TGF-b1
mice, we first induced TGF-b1 transgene expression by discontinuing oral doxycycline, followed by 15 weeks of observation. The
mice were considered having a disease phenotype when they
showed body weight loss in combination with muscle weakness by
grip strength. We observed variability in onset of disease
phenotype in mCK-tTA/TRE-TGF-b1 mice after TGF-b1 was
induced in the muscles. Among the 20 mice studied, 40% of the
mice showed body weight loss and muscles weakness within 2
weeks. Approximately 30% of the mice showed the phenotype
between 5 to12 weeks after the transgene induction, and 30% of
the mCK-tTA/TRE-TGF-b1 mice did not exhibit any phenotype
during the observation period of 15 weeks. To further characterize
the mouse phenotype, we defined the group of mice that showed
phenotype within 2 weeks as early onset (EO) and the rest of mice

Muscle function of the EO, LO and control mice were
examined one week after TGF-b1 was induced using a grip
strength assay. We observed that the hindlimb muscle strength of
the mice in the EO group was reduced by 11.2% (p,0.05) in
comparison with the control mice (Figure 1B). At this time point
grip strength of the mice in the LO group was not significantly
different from the control mice. For the mice that showed muscle
weakness, visible muscle atrophy of both forelimbs and hindlimbs
was observed (Figure 2A). The weight of gastrocnemius, tibialis
anterior, quadriceps, biceps brachii, diaphragm and triceps
muscles were significantly reduced (p,0.05) in these mice while
the changes of deltoid and masseter muscle were not statistically
significant (Figure 2B).
We performed H&E and Pico-Sirius red staining to examine
muscle pathology and fibrosis accumulation, respectively in
response to TGF-b1 expression. Quadriceps of six pairs of
littermate with either EO or LO group and 4 control mice were
examined after the TGF-b1 was over-expressed for 2 weeks. The
H&E staining showed that no obvious muscle regeneration,

Figure 1. Muscle weakness caused by TGF-b1 over-expression
in skeletal muscles after doxycycline removal. (A) Expression of
the TGF-b1 mRNA in various organs. TGF-b1 transcripts were detected in
the two muscles, quadriceps and diaphragm, examined (lanes 1 and 2),
but not in the brain, heart, lung, liver, kidney or ovary (lanes 3–7,
respectively). Lane 8 is a no RT control. (B) GSM showed that muscle
strength was significantly reduced in mice that developed early
phenotype but not the rest of the mice over-expressing TGF-b1. The
asterisks indicate significant differences with p,0.05.
doi:10.1371/journal.pone.0079356.g001

PLOS ONE | www.plosone.org

Figure 2. Skeletal muscle wasting due to TGF-b1 overexpression. (A) Skeletal muscle wasting in mice over-expressing
TGF-b1, which developed muscle weakness. (B) The average muscle
weight (g, mean 6 s.e.m.) was reduced in these mice. ‘‘*’’ indicates
p,0.05 and ‘‘**’’ indicates p,0.01.
doi:10.1371/journal.pone.0079356.g002
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degeneration or inflammation was induced in the muscles of the
mice over-expressing TGF-b1. However, the mice developed
excessive collagen deposition and the myofibers were smaller than
the control mice (Figure 3A). To quantify the atrophy of myofibers
observed in the muscles of the transgenic mice, we measured
muscle fiber diameters using minimal Feret’s diameter measurement [26]. Myofiber diameters shifted toward smaller in size in the
EO group (Figure 3 C). In addition, the mean myofiber diameters
of the mice in EO group was significantly smaller
(22.1761.12 mm, p,0.005) compared to those of the LO group
(28.2362.6 mm) and the control mice (34.8963.3 mm). The
myofibers of the LO group were also significantly smaller
(p,0.05) than the control mice. Collagen accumulation in the
mice of EO group was 2.9 folds higher than the mice in the LO
group (p,0.005) and 7.9 folds higher than the control mice
(p,0.001). The collagen deposition in the LO group was
significantly higher (p,0.05) than the control mice.

Endogenous TGF-b1 was Induced in the mCK-tTA/TRETGF-b1 Mice that Developed Phenotypes within 2 Weeks
To determine whether the disease severity is associated with the
expression level of the TGF-b1, both latent and active TGF-b1 in
serum and muscle of EO, LO and control groups were measured
by ELISA. To distinguish transgenic porcine TGF-b1 from
endogenous mouse TGF-b1 we compared level of active and
latent TGF-b1 since the transgene produces predominantly active
TGF-b1. Since the antibody does not distinguish between the
porcine TGF-b1 from the transgene and the endogenous murine
TGF-b1, the measurement of the active TGF-b1 is a mixture of
both. However, the measurements of the latent TGF-b1 indicate
only the endogenous murine TGF-b1. In mice of the EO group
both active and latent TGF-b1 in blood serum were significantly
(p,0.01) elevated compared to those in the LO’s group (Table 1
and Figure 4A). In addition, both active and latent TGF-b1 in
serum were also significantly (p,0.01) elevated in the mice of the
EO group compared to those in the control mice (Table 1 and

Figure 3. TGF-b1 over-expression leads to myofiber atrophy and endomysial fibrosis. (A) H&E and Pico-Sirius red staining showed smaller
myofibers and collagen accumulation in the mice over-expressing TGF-b1. The differences were less prominent in the mice that did not develop
muscle weakness at the time of muscle collection. Scale bar: 50 mm (B) Collagen deposition measurement after 2 weeks of TGF-b1 over-expression.
The mice in the EO group showed significantly higher collagen deposition in comparison to LO and control mice. ‘‘*’’ indicates p,0.05 and ‘‘**’’
indicates p,0.01. (C) Fiber size distribution after 2 weeks of TGF-b1 over-expression. The myofiber size was reduced in both the EO and LO groups
with more reduction in the EO group.
doi:10.1371/journal.pone.0079356.g003
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Figure 4A). The mice in the LO group did not show a significant
difference in either active or latent forms of TGF-b1 in
comparison to the control mice (Table 1and Figure 4A). Both
active and latent TGF-b1 in the muscle lysates were significantly
(p,0.01) elevated in the mice of the EO group compared to those
in the control or LO groups (Table 1 and Figure 4B). The active
and latent forms of TGF-b1 were not significantly different in the
mice of the LO group compared to the control mice (Table 1 and
Figure 4B).
A previous study showed that genetic polymorphism involving a
36-bp deletion within exon 12 in the latent transforming growth
factor binding protein-4 (Ltbp4) gene was able to affect the
activation of TGF-b1 [20]. The shorter allele with a 36-bp
deletion encodes an LTBP4 protein that enhances the release of
active TGF-b1 by increasing the proteolysis of the proline-rich
region of LTBP4 [20]. To determine whether this polymorphism
contributes to the phenotypic variations observed in the TGF-b1
transgenic mice, we examined Ltbp4 genotypes in these mice. The
PCR results showed no association between this genetic polymorphism and the EO/LO phenotypes (Figure S1).

Discussion
Increased levels of TGF-b1 have been demonstrated in DMD,
X-linked spinal and bulbar muscular atrophy, congenital muscular
dystrophies
and
inflammatory
myositis
patients
[5,22,23,27,28,29]. TGF-b1 is believed to play a critical role in
the fibrosis observed in the affected muscles and may contribute to
the failure of regeneration in some of the diseases such as DMD.
TGF-b1 promotes growth and differentiation of fibroblasts and is
a potent regulator of collagen synthesis [30,31]. In addition, TGFb1 can convert satellite cells into myofibroblasts, which promotes
fibrosis and potentially depletes the satellite cells for muscle
regeneration [16,30]. In addition to promoting fibrosis, TGF-b1
can suppress myoblasts differentiation in culture [32]. Local
delivery of TGF-b1 by single intramuscular or subcutaneous
injection into the hindlimbs of mice leads to muscle atrophy and
fibrosis phenotypes [16,33]. In one study, intramuscular injection
of 5 ng of TGF-b1 lead to inflammatory responses within 7 days,
which disappeared at a later time point. However, the inflammation was not observed in a second study in which 0.2 ng of TGFb1 was delivered by subcutaneously injection [16,33]. In our
study, we observed only endomysial fibrosis and muscle atrophy in
the mCK-tTA/TRE-TGF-b1 mouse model after the transgene was
over-expressed, without cellular infiltration observed in muscles,
suggesting that inflammation occurred in the first study might be
induced by a combination of the presence of TGF-b1 and muscle
injuries caused by the intramuscular injections.
Our study showed 22.43 pg of TGF-b1 per mg total protein in
skeletal muscles of control mice. Endomysial fibrosis and myofiber
atrophy were detected in the LO group of mice, which showed
4 fold-up-regulation of TGF-b1. No significant muscle weakness

Figure 4. Active and latent TGF-b1 levels in serum and
quadriceps after two weeks of TGF-b1 over-expression. (A) The
serum level of both active and latent TGF-b1 was significantly higher in
mice in the EO group in comparison to LO and control littermates. (B)
The level of both active and latent TGF-b1 in quadriceps was
significantly higher in mice in the EO group in comparison to LO and
control littermates. ‘‘*’’ indicates p,0.05 and ‘‘**’’ indicates p,0.01.
doi:10.1371/journal.pone.0079356.g004

was detected in these mice. In the EO group, an average of
234 fold up-regulation of active TGF-b1 lead to pathological
changes, muscle weight loss and muscle weakness. Our data
suggest a dose related response to TGF-b1 in vivo. When individual
muscles were examined, we observed that the response to TGF-b1
over-expression was muscle-type-specific. The loss of muscle mass
was most severe in diaphragm which has been shown to be more
affected in DMD and its animal models [33,34,35,36,37,38].
While the muscle fibrosis and myofibers atrophy are prominent
pathological changes in the mice over-expressing TGF-b1, we did
not observed degeneration/regeneration or overt inflammatory
responses in the muscles of these mice. TGF-b1 is a pleiotrophic
cytokine, which has both inflammatory and anti-inflammatory
effects [39]. Complete elimination of TGF-b1 in TGF-b12/2 mice
lead to intrauterine or premature death and excessive inflammatory responses in multiple tissues [40]. Suppression of TGF-b1
using neutralizing antibodies in mdx mice has been reported to
either increase skeletal muscle inflammation or have no obvious

Table 1. TGF-b1 protein levels in the blood serum and muscle lysates.

Mice

Serum (mean 6 s.e.m., ng/ml)

Muscle (mean 6 s.e.m., pg/mg of muscle)

Active

Active

Latent

Latent

Early Onset (EO)

23.2765.58

217.34618.87

5243.2561275.92

1194.336321.43

Late Onset (LO)

0.8360.22

75.2865.97

91.10657.81

42.52631.28

Control

0.5560.10

94.72619.48

22.4366.92

7.2460.57

doi:10.1371/journal.pone.0079356.t001
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[20,51]. The presence of doxycycline in cells inhibits binding of
tTA to the TRE and blocks TGF-b1 transgene expression (Figure
S2). After cross-breeding the TRE-TGF-b1 and mCK-tTA lines, the
pregnant female mice received drinking water with doxycycline
(200 mg/ml in 5.0% sucrose) in order to suppress the TGF-b1
transgene expression in the pups in utero. Under these conditions,
the TRE-TGF-b1/mCK-tTA transgenic mice were born at an
expected Mendelian ratio. After weaning, all pups were maintained on water treated with doxycycline until they were entered
into an experimental regiment. In this study, doxycycline was
removed from water to induce transgene expression in the TRETGF-b1/mCK-tTA mice along with control when the mice were
between 4 to 14 weeks old. For all experiments, littermates
carrying single transgene tTA were used as controls. Genotyping
primers used for polymerase chain reaction (PCR) were: TGF-b1,
forward, 59-GGGCTACCATGCCAATTTCTG–39; reverse, 59GTACAGAGCCAGGACCTTGCTG-39. tTA, forward, 59ACAGCGCATTAGAGCTGCTT-39;
reverse,
59CCCCTTCTAAAGGGCAAAAG-39. The PCR amplicons were
visualized using 2% agarose gels (Gibco BRL, Gaithersburg, MD).
The TGF-b1 primers target a 59UTR region that is specific to the
transgene therefore does not amplify murine Tgf-b1 gene. The age
of mice when TGF-b1 was induced and assays performed for
phenotype characterizations are summarized in table S1.

effect [24,41]. Our data showed that the severe endomysial fibrosis
induced by high level of TGF-b1 is independent of inflammation
in the muscle.
The time of onset was various after the TGF-b1 transgene was
induced in the mCK-tTA/TRE-TGF-b1 mice. Enzyme-linked
immunosorbent assays (ELISA) showed that the time of the onset
correlate to the amount of TGF-b1 in both the muscles and in
circulation. Interestingly, the protein level of the latent TGF-b1 in
the muscles was up-regulated in both EO and LO groups with a
significant difference between the two groups, indicating that the
endogenous TGF-b1 had been induced in the muscles with a
higher level in the mice that showed more severe phenotypes. The
findings suggest an autocrine regulation of TGF-b1 expression in
skeletal muscles. Since both the active and latent TGF-b1 were
also found up-regulated in sera, we cannot rule out the possibility
that other cell types such as fibroblasts and immune cells are
involved in the positive feedback loop as previously reported in
pancreatic stellate cells [42]. In this study we crossed two
transgenic lines to generate the mCK-tTA/TRE-TGF-b1 mice,
therefore the mice likely to carry more polymorphisms in their
genomes than pure breed lines. A polymorphism in Ltbp4 gene has
been shown to modulate TGF-b1 activation [20]. To determine
whether this polymorphism contributes to the phenotypic variations observed in the TGF-b1 transgenic mice, we examined Ltbp4
genotypes in these mice. Our results showed that this polymorphism did not contribute to the phenotypic variations observed
(Figure S1). Additional investigations are needed to identify genes
that modify the TGF-b1 activities in the mice.
A recent genetic study showed that a polymorphism in the
promoter of osteopontin (OPN), which reduces the expression
level of OPN, was associated with the more severe disease
phenotype in DMD [43]. Like TGF-b1, OPN has been associated
with fibrosis formation in different diseases [44,45,46]. The mdx
mice lacking OPN gene developed milder phenotype with
significant reduction of fibrosis [45]. The study conducted in mdx
mice suggested that OPN directly modulate TGF-b1 signaling
[45]. Interestingly, after two weeks of TGF-b1 expression,
expression of OPN is strongly induced in the mCK-tTA/TRETGF-b1 mice (unpublished microarray data). In addition, the
expression significantly correlated with the expression of TGF-b1
(r2 = 0.088), suggesting OPN may be part of the autocrine
feedback loop and modify the expression of TGF-b1.
While most studies reported negative regulatory role of TGF-b1
in myogenesis, others showed that TGF-b1 plays an essential role
in muscle regeneration [47,48,49]. This conditional musclespecific mouse model provides a useful tool for examining the
regulatory roles of TGF-b1 in skeletal muscles and for developing
strategies to modulate TGF-b1 in muscles.

Body and Muscle Mass
The TGF-b1 expression was induced in the muscles of twenty
7–14 weeks old TRE-TGF-b1/mCK-tTA mice by discontinuing
oral doxycycline. Thirteen female and seven male TRE-TGF-b1/
mCK-tTA mice, and their age- and gender-matched single
transgenic littermates were studied. The body weight of the mice
was measured 3 times a week starting from the date that the
doxycycline was stopped. Onset of the disease phenotype was
determined by weight loss and muscle strength measured by grip
strength test. The mice were euthanized for muscle collection at
the onset of the disease phenotype. Masseter, soleus, tibialis
anterior, quadriceps, gastrocnemius, deltoid, triceps, biceps brachii
and the diaphragm from three 12 weeks old female TRE-TGF-b1/
mCK-tTA transgenic mice and three control littermates were
dissected and immediately weighed to determine the muscle
weight changes.

Muscle Grip Strength Test
The muscle grip strength test was performed as previously
described [51]. The mice monitored for body weight changes were
tested for muscle strength two weeks after the TGF-b1 induction.
Briefly, the grip strength meter (GSM) (Columbus Instruments,
Columbus, OH) consists of two steel grids connected to force
meters. Grip strength is tested by holding the mouse over a grid of
GSM until the mouse can grip the steel bars. Then the mouse is
pulled away from the force meter until it releases the grid. The
meter recorded the maximum force that was applied. The mice
were acclimated to the GSM for five minutes one day prior to data
collection. They were then tested once a day for five consecutive
days. Five measurements were recorded for each test. The highest
values of the five tests each day were averaged and normalized to
body weight (kg).

Materials and Methods
Generation of Tet-repressible Muscle Specific Transgenic
TGF-b1 Mice
All animal procedures were approved by the institutional animal
care and use committee (IACUC) at the Children’s Research
Institute. Two transgenic mouse lines (TRE-TGF-b1 and mCK-tTA)
were cross-bred in order to generate the tet-repressible musclespecific TGF-b1 transgenic mice (TRE-TGF-b1/mCK-tTA). The
TRE-TGF-b1 line carries a porcine TGF-b1 cDNA containing a
double mutation where cysteines at positions 223 and 225 are
converted to serines, which is regulated by the tetO recognition
element (TRE) [50]. The mCK-tTA line carries a construct
containing the tetracycline-controlled transactivator (tTA) protein
driven by a muscle specific creatine kinase promoter (mCK)
PLOS ONE | www.plosone.org

Pico-Sirius Red and H&E Staining
TGF-b1 over-expression was induced when the mice were 4
weeks old then their muscles were collected after 2 weeks. Muscles
of six mice that showed body weight lost and muscle weakness
within two weeks (EP) and 6 littermates that did not show the
phenotype within 2 weeks (LP) were examined for pathological
5
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changes, changes of myofiber sizes and collagen accumulation.
Please note that the mice in the EO and LO groups were collected
in pairs from the same litters. Immediately after dissection, the
muscles were snap-frozen in isopentane cooled with liquid
nitrogen, then stored at 280uC. A Leica CM 1900 cryostat
(Walldorf, Baden-Wurttenberg, Germany) was used to prepare
cryosections for the pathohistological analysis. Hematoxylin and
Eosin (H&E) staining was conducted using 8 mm sections as
previously described [51]. Five random non-overlapping fields of
the tissue section (40X) were imaged using Nikon Eclipse E800
microscope (Nikon, Chiyoda-ku, Tokyo, Japan), RT slider camera
(Diagnostic Instrument, Sterling Height, MI) and SPOT advanced
software. The diameters of myofibers were determined by
measuring the minimal Feret’s diameter using the SPOT
Advanced software as previously described [51].
Pico-Sirius Red staining was performed to measure accumulated collagen in the gastrocnemius muscles. Nuclei of 8 mm muscle
sections were stained with Weigert’s Hematoxyline (Sigma
Aldrich, St. Louis, MO) for 5 minutes followed by Pico-Sirius
red (Sigma Aldrich, St. Louis, MO) staining for 1 hour. The
sections were washed using acidified water with 0.5% glacial acetic
acid (Sigma Aldrich, St. Louis, MO), dehydrated in 100% ethanol
then submerged in xylene. The digital images were processed
using Image J (http://rsb.info.nih.gov/ij). Pixels corresponding to
the area stained in red were normalized to the total pixel area of
the tissue and the results were expressed as percentage of collagen
accumulations [52].

of the active and latent TGF-b1 in muscles was determined using
muscles lysate. Quadriceps muscles were homogenized in RIPA
buffer prior to ELISA using the ELISA kit (R&D systems,
Minneapolis, MN).

Ltbp 4 Genotyping by Polymerase Chain Reaction (PCR)
We performed PCR to examine a polymorphism in Ltbp4 gene
that was reported to be associated with TGF-b1 activation [20].
The primers were: forward, 59-AGAACCCTGGACAGATG–39;
reverse, 59-TCCAAGCAGGGATGC-39. A 260 bp PCR amplicon represents the long allele and a 224 bp PCR amplicon
represents the short allele (36-bp deletion) were visualized using
2% agarose gels (Figure S1).

Supporting Information
Figure S1 No association between Ltbp 4 genotypes and
the phenotypes of mCK-tTA/TRE-TGF-b1 mice. The long
allele (260 bp) and short allele (224 bp) were not associated with
the early (EO, lane 1, 4, 6) and late (LO, lane 2, 3, 5) phenotypes.
Lane 7 and 8 show Ltbp 4 genotypes of 2 control mice.
(TIF)

Tet-repressible system of the mCK-tTA/TRETGF-b1 mice. The expression of tetracycline-controlled transactivator (tTA) is regulated by the promoter of muscle creatine
kinase (mCK). The TGF-b1 transgene expression is regulated by
tetracycline-response element (TRE) which consists of a heptameric tetO sequence and a minimal CMV promoter (PminCMV).
In the presence of doxycycline, the doxycycline will interact with
the tTA, which prevents the tTA bind to the TRE. In the absence
of doxycycline, the tTA binds the TRE, which activates
transcription of the TGF-b1 transgene.
(TIF)

Figure S2

Enzyme-linked Immunosorbent Assay (ELISA)
The amount of active TGF-b1 and total TGF-b1 (active and
latent) in skeletal muscles and sera was determined using TGF-b1
immunoassay system (R&D systems, Minneapolis, MN). The sera
were collected from the same 6 pairs of mice used for pathological
examinations. The sera were diluted 10 times and the active TGFb1 was determined using the ELISA plate pre-coated with TGFb1 specific antibody following the manufacture’s protocol. To
determine the amount of latent TGF-b1, the sera were treated
with 1N HCl to activate the latent TGF-b1 before measurement
using the ELISA kit. The amount of the latent TGF-b1 was then
be calculated by subtracting the amount of the active TGF-b1
from the total amount of TGF-b1 determined. The optical density
was determined at 450 nm within 30 minutes after the reactions
were stopped. The wavelength correction was performed by
subtracting the value at 570 nm from that at 450 nm. The amount

Table S1 The age of mice when TGF-b1 was induced
and assays performed for phenotype characterizations.
(DOC)
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